ATE260919T1 - Zwischenprodukte für die herstellung von pharmazeutischem camptothecin - Google Patents
Zwischenprodukte für die herstellung von pharmazeutischem camptothecinInfo
- Publication number
- ATE260919T1 ATE260919T1 AT95917217T AT95917217T ATE260919T1 AT E260919 T1 ATE260919 T1 AT E260919T1 AT 95917217 T AT95917217 T AT 95917217T AT 95917217 T AT95917217 T AT 95917217T AT E260919 T1 ATE260919 T1 AT E260919T1
- Authority
- AT
- Austria
- Prior art keywords
- camptothecin
- pharmaceutical
- production
- intermediate products
- chem
- Prior art date
Links
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title abstract 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 2
- 229940127093 camptothecin Drugs 0.000 title abstract 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000013067 intermediate product Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000543 intermediate Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/237,081 US5491237A (en) | 1994-05-03 | 1994-05-03 | Intermediates in pharmaceutical camptothecin preparation |
| PCT/US1995/005425 WO1995029917A2 (en) | 1994-05-03 | 1995-05-02 | Intermediates in pharmaceutical camptothecin preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE260919T1 true ATE260919T1 (de) | 2004-03-15 |
Family
ID=22892263
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95918904T ATE227292T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
| AT95917217T ATE260919T1 (de) | 1994-05-03 | 1995-05-02 | Zwischenprodukte für die herstellung von pharmazeutischem camptothecin |
| AT02014439T ATE289608T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95918904T ATE227292T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02014439T ATE289608T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US5491237A (de) |
| EP (3) | EP0758333B1 (de) |
| JP (2) | JPH09512559A (de) |
| AT (3) | ATE227292T1 (de) |
| AU (2) | AU2381695A (de) |
| DE (3) | DE69528762T2 (de) |
| DK (1) | DK0758335T3 (de) |
| ES (3) | ES2219661T3 (de) |
| WO (2) | WO1995029917A2 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559309B2 (en) | 1996-11-01 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Preparation of a camptothecin derivative by intramolecular cyclisation |
| US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| EP1512413A3 (de) | 2001-01-16 | 2009-09-23 | Glaxo Group Limited | Pharmazeutische Mischung gegen Krebs, die ein 4-Chinazolinamin in Kombination mit einem anderen antineoplastischen Wirkstoff enthält |
| US6809210B2 (en) | 2001-06-12 | 2004-10-26 | Lucent Technologies Inc. | Method of solvating a metal in an aromatic organic liquid |
| US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
| CZ299329B6 (cs) * | 2003-08-26 | 2008-06-18 | Pliva-Lachema A.S. | Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu |
| CZ299593B6 (cs) * | 2003-12-16 | 2008-09-10 | Pliva-Lachema A. S. | Zpusob výroby 7-ethyl-10-hydroxykamptothecinu |
| US8492456B2 (en) * | 2004-02-09 | 2013-07-23 | Hewlett-Packard Development Company, L.P. | Ink compositions for ink-jet printing |
| JP4861340B2 (ja) * | 2005-02-22 | 2012-01-25 | エフ．ホフマン−ラ ロシュ アーゲー | カンプトセシンサブユニットの新規の合成法 |
| TWI375678B (en) * | 2005-06-09 | 2012-11-01 | Yakult Honsha Kk | A method of preparation of a tricyclic ketone |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CN101888841B (zh) * | 2007-10-09 | 2012-09-26 | 宾夕法尼亚大学理事会 | 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞 |
| US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
| CA2750565C (en) | 2009-01-30 | 2015-10-20 | Glaxosmithkline Llc | Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| US8410095B2 (en) | 2009-05-20 | 2013-04-02 | Glaxosmithkline Llc | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors |
| CN101591342B (zh) * | 2009-07-03 | 2011-07-27 | 华东师范大学 | 用于喜树碱类化合物制备的关键中间体合成方法 |
| MX2012002426A (es) | 2009-08-26 | 2012-06-27 | Cylene Pharmaceuticals Inc | Quinolinas condensadas como moduladores de proteina cinasa. |
| CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| ES2616238T3 (es) | 2010-10-06 | 2017-06-12 | Glaxosmithkline Llc, Corporation Service Company | Derivados de bencimidazol como inhibidores de PI3 quinasa |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| MX2014006126A (es) | 2011-11-22 | 2015-03-19 | Deciphera Pharmaceuticals Llc | Amidas de piridona y analogos que exhiben actividades anticancerigenas y antiproliferativas. |
| RU2014135224A (ru) | 2012-01-31 | 2016-03-27 | Смитклайн Бичем (Корк) Лимитед | Способ лечения злокачественных опухолей |
| EP3181564B1 (de) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidinverbindungen als inhibitoren von t790m-haltigen egfr-mutanten |
| MA38121A1 (fr) | 2012-11-30 | 2016-10-31 | Glaxosmithkline Llc | Nouvelle composition pharmaceutique |
| CN104902896A (zh) | 2013-01-09 | 2015-09-09 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 组合 |
| EP2943484B1 (de) | 2013-01-10 | 2017-10-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Fettsäuresynthasehemmer |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| WO2015128837A1 (en) | 2014-02-26 | 2015-09-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3331919A1 (de) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationstherapie mit anti-ctla-4-antikörpern |
| US20190256608A1 (en) | 2015-12-01 | 2019-08-22 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
| KR20190090824A (ko) | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 암을 치료하는 방법 |
| KR20250026366A (ko) | 2017-07-05 | 2025-02-25 | 노파르티스 아게 | 신규한 약학적 조성물 |
| UY37866A (es) | 2017-09-07 | 2019-03-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| WO2020160375A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| KR20220026585A (ko) | 2019-06-26 | 2022-03-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Il1rap 결합 단백질 |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| EP4096718A1 (de) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationsbehandlungen und verwendungen und verfahren dafür |
| CN115073408A (zh) * | 2022-08-09 | 2022-09-20 | 江苏法安德医药科技有限公司 | 一种2,3,4,6-四苄基-d-吡喃葡萄糖的合成方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE152774C (de) * | ||||
| US4399282A (en) * | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| DD152774A1 (de) * | 1980-08-25 | 1981-12-09 | Brunhilde Gorski | Verfahren zur abtrennung von palladium und technetium aus loesungen der kernbrennstoffwiederaufbereitung |
| US4399276A (en) * | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4413118A (en) * | 1981-03-02 | 1983-11-01 | Merck & Co., Inc. | Process for removal of homogeneous catalyst group VIII metals from process streams |
| US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| DE3682874D1 (de) * | 1985-10-21 | 1992-01-23 | Daiichi Seiyaku Co | Pyranoindolizinderivate und verfahren zu ihrer herstellung. |
| JPS6314824A (ja) * | 1986-07-04 | 1988-01-22 | Tanaka Kikinzoku Kogyo Kk | 貴金属元素の回収方法 |
| JPS6333355A (ja) * | 1986-07-29 | 1988-02-13 | Mitsui Toatsu Chem Inc | シスチンの精製方法 |
| US5227380A (en) * | 1987-03-31 | 1993-07-13 | Research Triangle Institute | Pharmaceutical compositions and methods employing camptothecins |
| US5106742A (en) * | 1987-03-31 | 1992-04-21 | Wall Monroe E | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US4894456A (en) * | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US4981968A (en) * | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US5244903A (en) * | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US5053512A (en) * | 1987-04-14 | 1991-10-01 | Research Triangle Institute | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives |
| US5122526A (en) * | 1987-03-31 | 1992-06-16 | Research Triangle Institute | Camptothecin and analogs thereof and pharmaceutical compositions and method using them |
| US5122606A (en) * | 1987-04-14 | 1992-06-16 | Research Triangle Institute | 10,11-methylenedioxy camptothecins |
| US5180722A (en) * | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
| US5049668A (en) * | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| US4965364A (en) * | 1988-02-23 | 1990-10-23 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation |
| US5260461A (en) * | 1988-01-11 | 1993-11-09 | Massachusetts Institute Of Technology | Ligands for ADH: cinchona alkaloids and moderately sized organic substituents linked through a planar aromatic spacer group |
| US5227543A (en) * | 1988-01-11 | 1993-07-13 | Massachusetts Institute Of Technology | Facilitation of turnover in the ADH by additives which catalyze the hydrolysis of the OS(VI) glycolate esters |
| ATE178578T1 (de) * | 1988-01-11 | 1999-04-15 | Massachusetts Inst Technology | Durch einen komplexbilder beschleunigte asymmetrische katalytische dihydroxylierung |
| US4871855A (en) * | 1988-01-11 | 1989-10-03 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation using dihydroquinidine and dihydroquinidine esters as ligands |
| US5126494A (en) * | 1988-01-11 | 1992-06-30 | Massachusetts Institute Of Technology | Methods for catalytic asymmetric dihydroxylation of olefins |
| JPH0615547B2 (ja) * | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| DK0418099T3 (da) * | 1989-09-15 | 2002-04-02 | Res Triangle Inst | Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger |
| US5099047A (en) * | 1989-11-17 | 1992-03-24 | Mitsubishi Kasei Corporation | Method for recovering a group viii metal solid complex and hydroformylation method |
| IE913790A1 (en) * | 1990-10-31 | 1992-05-22 | Smithkline Beecham Corp | SUBSTITUTED INDOLIZINO [1,2-b]QUINOLINONES |
| US5247089A (en) * | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5243050A (en) * | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5264579A (en) * | 1990-12-20 | 1993-11-23 | North Carolina State University | D ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5212317A (en) * | 1990-12-20 | 1993-05-18 | North Carolina State University | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs |
| US5162532A (en) * | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5258516A (en) * | 1990-12-20 | 1993-11-02 | Nc State University | Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs |
| US5254690A (en) * | 1990-12-20 | 1993-10-19 | North Carolina State University | Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs |
| US5315007A (en) * | 1990-12-20 | 1994-05-24 | North Carolina State University | Process for making DE ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| JP3550397B2 (ja) * | 1991-05-13 | 2004-08-04 | マサチユセツツ・インスチチユート・オブ・テクノロジイ | 複素環式キラル配位子およびオレフィン類の接触非対称性ジヒドロキシル化方法 |
| ATE136898T1 (de) * | 1991-10-29 | 1996-05-15 | Glaxo Wellcome Inc | Wasserlösliche camptothecinderivate |
| EP0556585A3 (de) * | 1992-01-24 | 1993-09-01 | Takeda Chemical Industries, Ltd. | Kondensierte Camptotherinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
| WO1993016698A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
| EP0655919A4 (de) * | 1992-08-21 | 1995-10-18 | Dana Farber Cancer Inst Inc | Behandlung von virusinfektionen beim menschen. |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5479108A (en) * | 1992-11-25 | 1995-12-26 | David Cheng | Method and apparatus for handling wafers |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| ATE301659T1 (de) * | 1995-11-02 | 2005-08-15 | Osi Pharm Inc | Verfahren zur herstellung von campothecinderivate |
-
1994
- 1994-05-03 US US08/237,081 patent/US5491237A/en not_active Expired - Lifetime
-
1995
- 1995-05-02 ES ES95917217T patent/ES2219661T3/es not_active Expired - Lifetime
- 1995-05-02 DE DE69528762T patent/DE69528762T2/de not_active Expired - Fee Related
- 1995-05-02 JP JP7528482A patent/JPH09512559A/ja active Pending
- 1995-05-02 DE DE69532634T patent/DE69532634T2/de not_active Expired - Fee Related
- 1995-05-02 DK DK95918904T patent/DK0758335T3/da active
- 1995-05-02 DE DE69534029T patent/DE69534029T2/de not_active Expired - Fee Related
- 1995-05-02 AU AU23816/95A patent/AU2381695A/en not_active Abandoned
- 1995-05-02 AT AT95918904T patent/ATE227292T1/de not_active IP Right Cessation
- 1995-05-02 EP EP95917217A patent/EP0758333B1/de not_active Expired - Lifetime
- 1995-05-02 AT AT95917217T patent/ATE260919T1/de not_active IP Right Cessation
- 1995-05-02 JP JP7528481A patent/JPH09512558A/ja not_active Ceased
- 1995-05-02 ES ES02014439T patent/ES2238523T3/es not_active Expired - Lifetime
- 1995-05-02 EP EP02014439A patent/EP1254908B9/de not_active Expired - Lifetime
- 1995-05-02 WO PCT/US1995/005425 patent/WO1995029917A2/en not_active Ceased
- 1995-05-02 WO PCT/US1995/005427 patent/WO1995029919A1/en not_active Ceased
- 1995-05-02 AT AT02014439T patent/ATE289608T1/de not_active IP Right Cessation
- 1995-05-02 ES ES95918904T patent/ES2188661T3/es not_active Expired - Lifetime
- 1995-05-02 US US08/737,032 patent/US6063923A/en not_active Expired - Fee Related
- 1995-05-02 AU AU24651/95A patent/AU2465195A/en not_active Abandoned
- 1995-05-02 US US08/732,435 patent/US5840898A/en not_active Expired - Fee Related
- 1995-05-02 EP EP95918904A patent/EP0758335B1/de not_active Expired - Lifetime
-
2000
- 2000-04-19 US US09/552,214 patent/US6462196B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1254908A1 (de) | 2002-11-06 |
| AU2465195A (en) | 1995-11-29 |
| WO1995029917A3 (en) | 1995-12-28 |
| EP0758333A1 (de) | 1997-02-19 |
| ES2238523T3 (es) | 2005-09-01 |
| US5840898A (en) | 1998-11-24 |
| EP1254908B1 (de) | 2005-02-23 |
| US6462196B1 (en) | 2002-10-08 |
| JPH09512559A (ja) | 1997-12-16 |
| DE69532634T2 (de) | 2005-03-10 |
| ATE227292T1 (de) | 2002-11-15 |
| WO1995029919A1 (en) | 1995-11-09 |
| HK1052687A1 (en) | 2003-09-26 |
| US5491237A (en) | 1996-02-13 |
| AU2381695A (en) | 1995-11-29 |
| ATE289608T1 (de) | 2005-03-15 |
| DE69532634D1 (de) | 2004-04-08 |
| ES2188661T3 (es) | 2003-07-01 |
| WO1995029917A2 (en) | 1995-11-09 |
| JPH09512558A (ja) | 1997-12-16 |
| DE69528762D1 (de) | 2002-12-12 |
| DK0758335T3 (da) | 2003-03-17 |
| EP0758335B1 (de) | 2002-11-06 |
| DE69534029T2 (de) | 2006-01-12 |
| DE69534029D1 (de) | 2005-03-31 |
| EP0758335A1 (de) | 1997-02-19 |
| EP1254908B9 (de) | 2005-09-21 |
| DE69528762T2 (de) | 2003-07-17 |
| ES2219661T3 (es) | 2004-12-01 |
| US6063923A (en) | 2000-05-16 |
| EP0758333B1 (de) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69532634D1 (de) | Zwischenprodukte für die herstellung von pharmazeutischem camptothecin | |
| NO303574B1 (no) | Ny fremgangsmÕte for fremstilling av 9-amino-6-demetyl-6-deoksytetracykliner | |
| PH25459A (en) | Compound useful in the production of quinoline, naphthyridine carboxylic acids useful as antibacterials | |
| ATE38661T1 (de) | Zwischenprodukt und verfahren zu dessen herstellung. | |
| EP0902022A4 (de) | Benzofuranon-derivate und verfahren zu ihrer herstellung | |
| ES8606282A1 (es) | Un procedimiento de preparar derivados de acidos quinolin- ynaftiridin-carboxilicos | |
| DK546489A (da) | Thienopyridin-mevalonolactoner, fremgangsmaade til fremstilling heraf og farmaceutisk praeparat omfattende samme | |
| DE3576952D1 (de) | Verfahren zur herstellung von 4-phenyl-pyrrol-derivaten. | |
| PT89207A (pt) | Processo para a preparcao de derivados de ciclopropano e de produtos intermediarios | |
| ATE201410T1 (de) | Verfahren zur herstellung von 1-(4,5-dihydro)2- thiazolyl-3-azetidinthiolderivaten | |
| ATE46322T1 (de) | Verfahren zur herstellung von bestatin-derivaten und deren zwischenprodukte. | |
| DE69229017D1 (de) | Glyceraldehyd-3-pentanid und Verfahren zu ihrer Herstellung | |
| ATE75739T1 (de) | Verfahren zur herstellung von dibenzothiepinderivaten. | |
| DE3880880D1 (de) | 3-(6'-methoxy-2'-naphthylmethyl)-2,4-pentandion, verfahren zur herstellung und zwischenprodukte. | |
| ATE109771T1 (de) | Verfahren zur herstellung von azetidinonen. | |
| ATE206109T1 (de) | Verfahren zur herstellung von carbamoylmethylharnstoff-derivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |